Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

ABSTRACT: 17 patients with myelofibrosis contributed paired research samples; the time points were pre-study and 12 weeks after commencing study treatment with CYT387.Gene expression analysis was investigated to study the effects of drug treatment. Additional analysis invesitigated differences in expression patterns in groups of anemia responders and non-responders following drug treatment. 34 samples representing 17 patients. Each patient submitted 1 pre-treatment sample and 1 post 12 weeks of treatment.

ORGANISM(S): Homo sapiens

SUBMITTER: Animesh Pardanani 

PROVIDER: E-GEOD-40841 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress